← Back to Research Hub

Retatrutide Metabolic / GLP-1 / GIP

Overview

Retatrutide is a lab-made peptide that goes a step further than tirzepatide — it acts on three hormone receptors at once: GLP-1, GIP, and glucagon.

Research Context

Adding glucagon receptor activity is what sets it apart, since glucagon affects how the body burns energy, not just blood sugar and appetite. In phase 2 human trials, it produced substantial weight loss — an average of 24.2% after 48 weeks in people with obesity. In a separate trial in people with type 2 diabetes, it significantly improved blood sugar control. A pooled analysis of multiple trials also found reductions in waist size and fasting blood sugar.

Cited Sources

• Retatrutide – A Game Changer in Obesity Pharmacotherapy (PubMed)
• Efficacy and safety of retatrutide, meta-analysis (PubMed)

Storage & Handling

Protect from light and temperature extremes.

Related COA: View on Lab Results